{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:28:55Z","timestamp":1794432535912,"version":"4.9.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-09-BLAN-0265 GENETOL"],"award-info":[{"award-number":["ANR-09-BLAN-0265 GENETOL"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-17-CE17-0007-01 TOLGEN"],"award-info":[{"award-number":["ANR-17-CE17-0007-01 TOLGEN"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-09-BLAN-0265 GENETOL"],"award-info":[{"award-number":["ANR-09-BLAN-0265 GENETOL"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-17-CE17-0007-01 TOLGEN"],"award-info":[{"award-number":["ANR-17-CE17-0007-01 TOLGEN"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1038\/s41434-025-00514-z","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T14:23:01Z","timestamp":1737469381000},"page":"287-298","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Incomplete elimination of viral genomes is associated with chronic inflammation in nonhuman primate livers after AAV-mediated gene transfer"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8983-6446","authenticated-orcid":false,"given":"Virginie","family":"Pichard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micka\u00ebl","family":"Guilbaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Devaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Jaulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malo","family":"Journou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9513-1024","authenticated-orcid":false,"given":"Magalie","family":"Cospolite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3031-5199","authenticated-orcid":false,"given":"Alexandra","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Ferry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Michalak-provost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwladys","family":"Gernoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oumeya","family":"Adjali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"key":"514_CR1","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00439-006-0165-6","volume":"119","author":"KH Warrington Jr","year":"2006","unstructured":"Warrington KH Jr, Herzog RW. Treatment of human disease by adeno-associated viral gene transfer. Hum Genet. 2006;119:571\u2013603.","journal-title":"Hum Genet"},{"key":"514_CR2","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.hoc.2017.06.011","volume":"31","author":"AC Nathwani","year":"2017","unstructured":"Nathwani AC, Davidoff AM, Tuddenham EGD. Gene therapy for hemophilia. Hematol\/Oncol Clin North Am. 2017;31:853\u201368.","journal-title":"Hematol\/Oncol Clin North Am"},{"key":"514_CR3","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.visres.2014.07.013","volume":"111","author":"LS Carvalho","year":"2015","unstructured":"Carvalho LS, Vandenberghe LH. Promising and delivering gene therapies for vision loss. Vis Res. 2015;111:124\u201333.","journal-title":"Vis Res"},{"key":"514_CR4","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1089\/hum.2016.087","volume":"27","author":"M Hocquemiller","year":"2016","unstructured":"Hocquemiller M, Giersch L, Audrain M, Parker S, Cartier N. Adeno-associated virus-based gene therapy for CNS diseases. Hum Gene Ther. 2016;27:478\u201396.","journal-title":"Hum Gene Ther"},{"key":"514_CR5","doi-asserted-by":"publisher","unstructured":"Hudry E, Aihara F, Meseck E, Mansfield K, McElroy C, Chand D, et al. Liver injury in cynomolgus monkeys following intravenous and intrathecal scAAV9 gene therapy delivery. Mol Therapy. 2023. https:\/\/doi.org\/10.1016\/j.ymthe.2023.07.020.","DOI":"10.1016\/j.ymthe.2023.07.020"},{"key":"514_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1001263","volume":"13","author":"W Shen","year":"2022","unstructured":"Shen W, Liu S, Ou L. rAAV immunogenicity, toxicity, and durability in 255 clinical trials: a meta-analysis. Front Immunol. 2022;13:1001263.","journal-title":"Front Immunol"},{"key":"514_CR7","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1089\/hum.2020.217","volume":"31","author":"PB Shieh","year":"2020","unstructured":"Shieh PB, B\u00f6nnemann CG, M\u00fcller-Felber W, Blaschek A, Dowling JJ, Kuntz NL, et al. Re: \u2018Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy\u2019 by Wilson and Flotte. Hum Gene Ther. 2020;31:787.","journal-title":"Hum Gene Ther"},{"key":"514_CR8","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1182\/blood.V97.12.3733","volume":"97","author":"Y Ge","year":"2001","unstructured":"Ge Y, Powell S, Van Roey M, McArthur JG. Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX. Blood. 2001;97:3733\u20137.","journal-title":"Blood"},{"key":"514_CR9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1089\/104303401750061267","volume":"12","author":"L Cordier","year":"2001","unstructured":"Cordier L, Gao GP, Hack AA, McNally EM, Wilson JM, Chirmule N, et al. Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies. Hum Gene Ther. 2001;12:205\u201315.","journal-title":"Hum Gene Ther"},{"key":"514_CR10","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1006\/mthe.2001.0441","volume":"4","author":"PA Fields","year":"2001","unstructured":"Fields PA, Arruda VR, Armstrong E, Chu K, Mingozzi F, Hagstrom JN, et al. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9. Mol Ther: J Am Soc Gene Ther. 2001;4:201\u201310.","journal-title":"Mol Ther: J Am Soc Gene Ther"},{"key":"514_CR11","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.ymthe.2005.04.024","volume":"12","author":"LM Franco","year":"2005","unstructured":"Franco LM, Sun B, Yang X, Bird A, Zhang H, Schneider A, et al. Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II. Mol Ther: J Am Soc Gene Ther. 2005;12:876\u201384.","journal-title":"Mol Ther: J Am Soc Gene Ther"},{"key":"514_CR12","doi-asserted-by":"publisher","first-page":"4226","DOI":"10.1182\/blood-2004-03-0848","volume":"105","author":"L Wang","year":"2005","unstructured":"Wang L, Dobrzynski E, Schlachterman A, Cao O, Herzog RW. Systemic protein delivery by muscle-gene transfer is limited by a local immune response. Blood. 2005;105:4226\u201334.","journal-title":"Blood"},{"key":"514_CR13","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1128\/JVI.75.1.269-277.2001","volume":"75","author":"A Sarukhan","year":"2001","unstructured":"Sarukhan A, Camugli S, Gjata B, von Boehmer H, Danos O, Jooss K. Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors. J Virol. 2001;75:269\u201377.","journal-title":"J Virol"},{"key":"514_CR14","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1089\/hum.2010.194","volume":"22","author":"P Bell","year":"2011","unstructured":"Bell P, Gao G, Haskins ME, Wang L, Sleeper M, Wang H, et al. Evaluation of adeno-associated viral vectors for liver-directed gene transfer in dogs. Hum Gene Ther. 2011;22:985\u201397.","journal-title":"Hum Gene Ther"},{"key":"514_CR15","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/223472a0","volume":"223","author":"RY Calne","year":"1969","unstructured":"Calne RY, Sells RA, Pena JR, Davis DR, Millard PR, Herbertson BM, et al. Induction of immunological tolerance by porcine liver allografts. Nature. 1969;223:472\u20136.","journal-title":"Nature"},{"key":"514_CR16","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/j.transproceed.2005.03.070","volume":"37","author":"R Girlanda","year":"2005","unstructured":"Girlanda R, Rela M, Williams R, O\u2019Grady JG, Heaton ND. Long-term outcome of immunosuppression withdrawal after liver transplantation. Transplant Proc. 2005;37:1708\u20139.","journal-title":"Transplant Proc"},{"key":"514_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1055\/s-0029-1192058","volume":"29","author":"SJ Knechtle","year":"2009","unstructured":"Knechtle SJ, Kwun J. Unique aspects of rejection and tolerance in liver transplantation. Semin Liver Dis. 2009;29:91\u2013101.","journal-title":"Semin Liver Dis"},{"key":"514_CR18","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1034\/j.1600-6143.2003.00050.x","volume":"3","author":"C Creput","year":"2003","unstructured":"Creput C, Durrbach A, Samuel D, Eschwege P, Amor M, Kriaa F, et al. Incidence of renal and liver rejection and patient survival rate following combined liver and kidney transplantation. Am J Transplant: Off J Am Soc Transplant Am Soc Transpl Surg. 2003;3:348\u201356.","journal-title":"Am J Transplant: Off J Am Soc Transplant Am Soc Transpl Surg"},{"key":"514_CR19","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.3389\/fimmu.2020.01044","volume":"11","author":"H Dai","year":"2020","unstructured":"Dai H, Zheng Y, Thomson AW, Rogers NM. Transplant tolerance induction: insights from the liver. Front Immunol. 2020;11:1044.","journal-title":"Front Immunol"},{"key":"514_CR20","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1159\/000456584","volume":"35","author":"D Wieland","year":"2017","unstructured":"Wieland D, Hofmann M, Thimme R. Overcoming CD8+ T-cell exhaustion in viral hepatitis: lessons from the mouse model and clinical perspectives. Dig Dis. 2017;35:334\u20138.","journal-title":"Dig Dis"},{"key":"514_CR21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3389\/fimmu.2013.00207","volume":"4","author":"G Germanidis","year":"2013","unstructured":"Germanidis G, Argentou N, Hytiroglou P, Vassiliadis T, Patsiaoura K, Germenis AE, et al. Liver FOXP3 and PD1\/PDL1 expression is down-regulated in chronic HBV hepatitis on maintained remission related to the degree of inflammation. Front Immunol. 2013;4:207.","journal-title":"Front Immunol"},{"key":"514_CR22","doi-asserted-by":"publisher","first-page":"E1517","DOI":"10.3390\/ijms18071517","volume":"18","author":"H Cho","year":"2017","unstructured":"Cho H, Kang H, Lee HH, Kim CW. Programmed cell death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) in viral hepatitis. Int J Mol Sci. 2017;18:E1517.","journal-title":"Int J Mol Sci"},{"key":"514_CR23","doi-asserted-by":"publisher","first-page":"104","DOI":"10.2174\/156652309787909490","volume":"9","author":"PA LoDuca","year":"2009","unstructured":"LoDuca PA, Hoffman BE, Herzog RW. Hepatic gene transfer as a means of tolerance induction to transgene products. Curr Gene Ther. 2009;9:104\u201314.","journal-title":"Curr Gene Ther"},{"key":"514_CR24","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1182\/blood-2007-03-080093","volume":"110","author":"F Mingozzi","year":"2007","unstructured":"Mingozzi F, Hasbrouck NC, Basner-Tschakarjan E, Edmonson SA, Hui DJ, Sabatino DE, et al. Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood. 2007;110:2334\u201341.","journal-title":"Blood"},{"key":"514_CR25","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1089\/hum.2008.161","volume":"20","author":"M Cooper","year":"2009","unstructured":"Cooper M, Nayak S, Hoffman BE, Terhorst C, Cao O, Herzog RW. Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer. Hum Gene Ther. 2009;20:767\u201376.","journal-title":"Hum Gene Ther"},{"key":"514_CR26","doi-asserted-by":"publisher","first-page":"16083","DOI":"10.1038\/mtm.2016.83","volume":"3","author":"GQ Perrin","year":"2016","unstructured":"Perrin GQ, Zolotukhin I, Sherman A, Biswas M, de Jong YP, Terhorst C, et al. Dynamics of antigen presentation to transgene product-specific CD4(+) T cells and of Treg induction upon hepatic AAV gene transfer. Mol Ther Methods Clin Dev. 2016;3:16083.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"514_CR27","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1089\/hum.2011.063","volume":"23","author":"P Zhang","year":"2012","unstructured":"Zhang P, Sun B, Osada T, Rodriguiz R, Yang XY, Luo X, et al. Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease. Hum Gene Ther. 2012;23:460\u201372.","journal-title":"Hum Gene Ther"},{"key":"514_CR28","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/mt.2010.64","volume":"18","author":"WH Yiu","year":"2010","unstructured":"Yiu WH, Lee YM, Peng WT, Pan CJ, Mead PA, Mansfield BC, et al. Complete normalization of hepatic G6PC deficiency in murine glycogen storage disease type Ia using gene therapy. Mol Ther: J Am Soc Gene Ther. 2010;18:1076\u201384.","journal-title":"Mol Ther: J Am Soc Gene Ther"},{"key":"514_CR29","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.omtm.2019.04.005","volume":"13","author":"S-O Han","year":"2019","unstructured":"Han S-O, Ronzitti G, Arnson B, Leborgne C, Li S, Mingozzi F, et al. Erratum: low-dose liver-targeted gene therapy for pompe disease enhances therapeutic efficacy of ERT via immune tolerance induction. Mol Ther Methods Clin Dev. 2019;13:431.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"514_CR30","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1089\/hum.2009.060","volume":"20","author":"G Gao","year":"2009","unstructured":"Gao G, Wang Q, Calcedo R, Mays L, Bell P, Wang L, et al. Adeno-associated virus-mediated gene transfer to nonhuman primate liver can elicit destructive transgene-specific T cell responses. Hum Gene Ther. 2009;20:930\u201342.","journal-title":"Hum Gene Ther"},{"key":"514_CR31","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1038\/mt.2008.87","volume":"16","author":"A Toromanoff","year":"2008","unstructured":"Toromanoff A, Ch\u00e9rel Y, Guilbaud M, Penaud-Budloo M, Snyder RO, Haskins ME, et al. Safety and efficacy of regional intravenous (RI) versus intramuscular (IM) delivery of rAAV1 and rAAV8 to nonhuman primate skeletal muscle. Mol Ther. 2008;16:1291\u20139.","journal-title":"Mol Ther"},{"key":"514_CR32","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.omtm.2021.02.003","volume":"20","author":"G Gernoux","year":"2021","unstructured":"Gernoux G, Guilbaud M, Devaux M, Journou M, Pichard V, Jaulin N, et al. AAV8 locoregional delivery induces long-term expression of an immunogenic transgene in macaques despite persisting local inflammation. Mol Ther Methods Clin Dev. 2021;20:660\u201374.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"514_CR33","doi-asserted-by":"publisher","unstructured":"Greig JA, Martins KM, Breton C, Lamontagne RJ, Zhu Y, He Z, et al. Integrated vector genomes may contribute to long-term expression in primate liver after AAV administration. Nat Biotechnol. 2023. https:\/\/doi.org\/10.1038\/s41587-023-01974-7.","DOI":"10.1038\/s41587-023-01974-7"},{"key":"514_CR34","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/mt.2009.267","volume":"18","author":"GE Talbot","year":"2010","unstructured":"Talbot GE, Waddington SN, Bales O, Tchen RC, Antoniou MN. Desmin-regulated lentiviral vectors for skeletal muscle gene transfer. Mol Ther. 2010;18:601\u20138.","journal-title":"Mol Ther"},{"key":"514_CR35","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1016\/j.biomaterials.2011.11.084","volume":"33","author":"S-J Kim","year":"2012","unstructured":"Kim S-J, Ise H, Goto M, Akaike T. Interactions of vimentin- or desmin-expressing liver cells with N-acetylglucosamine-bearing polymers. Biomaterials. 2012;33:2154\u201364.","journal-title":"Biomaterials"},{"key":"514_CR36","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1053\/j.gastro.2011.04.002","volume":"141","author":"E Breous","year":"2011","unstructured":"Breous E, Somanathan S, Bell P, Wilson JM. Inflammation promotes the loss of adeno-associated virus\u2013mediated transgene expression in mouse liver. Gastroenterology. 2011;141:348\u2013357.e3.","journal-title":"Gastroenterology"},{"key":"514_CR37","doi-asserted-by":"publisher","first-page":"e67748","DOI":"10.1371\/journal.pone.0067748","volume":"8","author":"I Gil-Fari\u00f1a","year":"2013","unstructured":"Gil-Fari\u00f1a I, Di Scala M, Vanrell L, Olag\u00fce C, Vales A, High KA, et al. IL12-mediated liver inflammation reduces the formation of AAV transcriptionally active forms but has no effect over preexisting AAV transgene expression. PLoS One. 2013;8:e67748.","journal-title":"PLoS One"},{"key":"514_CR38","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1006\/mthe.2001.0318","volume":"3","author":"RS Sung","year":"2001","unstructured":"Sung RS, Qin L, Bromberg JS. TNFalpha and IFNgamma induced by innate anti-adenoviral immune responses inhibit adenovirus-mediated transgene expression. Mol Ther. 2001;3:757\u201367.","journal-title":"Mol Ther"},{"key":"514_CR39","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1053\/gast.2002.33367","volume":"122","author":"MJP Arthur","year":"2002","unstructured":"Arthur MJP. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology. 2002;122:1525\u20138.","journal-title":"Gastroenterology"},{"key":"514_CR40","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1056\/NEJM200102083440604","volume":"344","author":"P Hammel","year":"2001","unstructured":"Hammel P, Couvelard A, O\u2019Toole D, Ratouis A, Sauvanet A, Fl\u00e9jou JF, et al. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N. Engl J Med. 2001;344:418\u201323.","journal-title":"N. Engl J Med"},{"key":"514_CR41","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1053\/j.gastro.2004.03.017","volume":"126","author":"P Farci","year":"2004","unstructured":"Farci P, Roskams T, Chessa L, Peddis G, Mazzoleni AP, Scioscia R, et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology. 2004;126:1740\u20139.","journal-title":"Gastroenterology"},{"key":"514_CR42","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.jhep.2014.04.026","volume":"61","author":"A Boltjes","year":"2014","unstructured":"Boltjes A, Movita D, Boonstra A, Woltman AM. The role of Kupffer cells in hepatitis B and hepatitis C virus infections. J Hepatol. 2014;61:660\u201371.","journal-title":"J Hepatol"},{"key":"514_CR43","unstructured":"Hordeaux J, Lamontagne RJ, Song C, Buchlis G, Dyer C, Buza EL, et al. High-dose systemic adeno-associated virus vector administration causes liver and sinusoidal endothelial cell injury. Mol Ther. 2024; S1525-0016(24)00071\u20136."},{"key":"514_CR44","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1002\/hep.22500","volume":"48","author":"M Zeremski","year":"2008","unstructured":"Zeremski M, Petrovic LM, Chiriboga L, Brown QB, Yee HT, Kinkhabwala M, et al. Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology. 2008;48:1440\u201350.","journal-title":"Hepatology"},{"key":"514_CR45","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1128\/JVI.01388-08","volume":"83","author":"KJ Helbig","year":"2009","unstructured":"Helbig KJ, Ruszkiewicz A, Lanford RE, Berzsenyi MD, Harley HA, McColl SR, et al. Differential expression of the CXCR3 ligands in chronic hepatitis C virus (HCV) infection and their modulation by HCV in vitro. J Virol. 2009;83:836\u201346.","journal-title":"J Virol"},{"key":"514_CR46","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/j.1478-3231.2011.02504.x","volume":"31","author":"F Tacke","year":"2011","unstructured":"Tacke F, Zimmermann HW, Berres M-L, Trautwein C, Wasmuth HE. Serum chemokine receptor CXCR3 ligands are associated with progression, organ dysfunction and complications of chronic liver diseases. Liver Int. 2011;31:840\u20139.","journal-title":"Liver Int"},{"key":"514_CR47","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1053\/j.gastro.2009.03.053","volume":"137","author":"HE Wasmuth","year":"2009","unstructured":"Wasmuth HE, Lammert F, Zaldivar MM, Weiskirchen R, Hellerbrand C, Scholten D, et al. Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology. 2009;137:309\u201319. 319.e1\u20133","journal-title":"Gastroenterology"},{"key":"514_CR48","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1002\/hep.25545","volume":"55","author":"H Sahin","year":"2012","unstructured":"Sahin H, Borkham-Kamphorst E, Kuppe C, Zaldivar MM, Grouls C, Al-samman M, et al. Chemokine Cxcl9 attenuates liver fibrosis-associated angiogenesis in mice. Hepatology. 2012;55:1610\u20139.","journal-title":"Hepatology"},{"key":"514_CR49","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/hep.24756","volume":"55","author":"N Sakai","year":"2012","unstructured":"Sakai N, Van Sweringen HL, Schuster R, Blanchard J, Burns JM, Tevar AD, et al. Receptor activator of nuclear factor-\u03baB ligand (RANKL) protects against hepatic ischemia\/reperfusion injury in mice. Hepatology. 2012;55:888\u201397.","journal-title":"Hepatology"},{"key":"514_CR50","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.jhep.2005.05.034","volume":"43","author":"AR Moschen","year":"2005","unstructured":"Moschen AR, Kaser A, Stadlmann S, Millonig G, Kaser S, M\u00fchllechner P, et al. The RANKL\/OPG system and bone mineral density in patients with chronic liver disease. J Hepatol. 2005;43:973\u201383.","journal-title":"J Hepatol"},{"key":"514_CR51","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S0168-8278(02)00435-X","volume":"38","author":"F Szalay","year":"2003","unstructured":"Szalay F, Hegedus D, Lakatos PL, Tornai I, Bajnok E, Dunkel K, et al. High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. J Hepatol. 2003;38:395\u2013400.","journal-title":"J Hepatol"},{"key":"514_CR52","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1002\/hep.27332","volume":"61","author":"E Seki","year":"2015","unstructured":"Seki E, Schwabe RF. Hepatic inflammation and fibrosis: functional links and key pathways. Hepatology. 2015;61:1066\u201379.","journal-title":"Hepatology"},{"key":"514_CR53","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1136\/gut.46.2.260","volume":"46","author":"PH McGuinness","year":"2000","unstructured":"McGuinness PH, Painter D, Davies S, McCaughan GW. Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particularly interleukin 18) in chronic hepatitis C infection. Gut. 2000;46:260\u20139.","journal-title":"Gut"},{"key":"514_CR54","first-page":"963","volume":"150","author":"SI Khakoo","year":"1997","unstructured":"Khakoo SI, Soni PN, Savage K, Brown D, Dhillon AP, Poulter LW, et al. Lymphocyte and macrophage phenotypes in chronic hepatitis C infection. Correlation with disease activity. Am J Pathol. 1997;150:963\u201370.","journal-title":"Am J Pathol"},{"key":"514_CR55","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/nature05115","volume":"443","author":"CL Day","year":"2006","unstructured":"Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006;443:350\u20134.","journal-title":"Nature"},{"key":"514_CR56","doi-asserted-by":"publisher","first-page":"11398","DOI":"10.1128\/JVI.01177-06","volume":"80","author":"S Urbani","year":"2006","unstructured":"Urbani S, Amadei B, Tola D, Massari M, Schivazappa S, Missale G, et al. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol. 2006;80:11398\u2013403.","journal-title":"J Virol"},{"key":"514_CR57","doi-asserted-by":"publisher","first-page":"288","DOI":"10.5009\/gnl14368","volume":"10","author":"H Cho","year":"2016","unstructured":"Cho H, Kang H, Kim CW, Kim HY, Jang JW, Yoon SK, et al. Phenotypic characteristics of PD-1 and CTLA-4 expression in symptomatic acute hepatitis A. Gut Liver. 2016;10:288\u201394.","journal-title":"Gut Liver"},{"key":"514_CR58","doi-asserted-by":"publisher","first-page":"186","DOI":"10.5009\/gnl.2014.8.2.186","volume":"8","author":"P Xu","year":"2014","unstructured":"Xu P, Chen Y-J, Chen H, Zhu X-Y, Song H-F, Cao L-J, et al. The expression of programmed death-1 in circulating CD4+ and CD8+ T cells during hepatitis B virus infection progression and its correlation with clinical baseline characteristics. Gut Liver. 2014;8:186\u201395.","journal-title":"Gut Liver"},{"key":"514_CR59","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1053\/j.gastro.2008.03.037","volume":"134","author":"Z Zhang","year":"2008","unstructured":"Zhang Z, Zhang J-Y, Wherry EJ, Jin B, Xu B, Zou Z-S, et al. Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B. Gastroenterology. 2008;134:1938\u201349. 1949.e1\u20133","journal-title":"Gastroenterology"},{"key":"514_CR60","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.ymthe.2020.01.004","volume":"28","author":"G Gernoux","year":"2020","unstructured":"Gernoux G, Gruntman AM, Blackwood M, Zieger M, Flotte TR, Mueller C. Muscle-directed delivery of an AAV1 vector leads to capsid-specific T cell exhaustion in nonhuman primates and humans. Mol Ther. 2020;28:747\u201357.","journal-title":"Mol Ther"},{"key":"514_CR61","doi-asserted-by":"publisher","first-page":"5310","DOI":"10.1172\/JCI70314","volume":"123","author":"C Mueller","year":"2013","unstructured":"Mueller C, Chulay JD, Trapnell BC, Humphries M, Carey B, Sandhaus RA, et al. Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression. J Clin Invest. 2013;123:5310\u20138.","journal-title":"J Clin Invest"},{"key":"514_CR62","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jhep.2007.03.023","volume":"47","author":"SM Ward","year":"2007","unstructured":"Ward SM, Fox BC, Brown PJ, Worthington J, Fox SB, Chapman RW, et al. Quantification and localisation of FOXP3+ T lymphocytes and relation to hepatic inflammation during chronic HCV infection. J Hepatol. 2007;47:316\u201324.","journal-title":"J Hepatol"},{"key":"514_CR63","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/hep.20649","volume":"41","author":"JN Stoop","year":"2005","unstructured":"Stoop JN, van der Molen RG, Baan CC, van der Laan LJW, Kuipers EJ, Kusters JG, et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology. 2005;41:771\u20138.","journal-title":"Hepatology"},{"key":"514_CR64","doi-asserted-by":"publisher","first-page":"e0156604","DOI":"10.1371\/journal.pone.0156604","volume":"11","author":"SG Amoras Eda","year":"2016","unstructured":"Amoras Eda SG, Gomes STM, Freitas FB, Santana BB, Ishak G, Ferreira de Ara\u00fajo MT, et al. Intrahepatic mRNA expression of FAS, FASL, and FOXP3 genes is associated with the pathophysiology of chronic HCV infection. PLoS One. 2016;11:e0156604.","journal-title":"PLoS One"},{"key":"514_CR65","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1002\/hep.23745","volume":"52","author":"SA Wuensch","year":"2010","unstructured":"Wuensch SA, Spahn J, Crispe IN. Direct, help-independent priming of CD8+ T cells by adeno-associated virus-transduced hepatocytes. Hepatology. 2010;52:1068\u201377.","journal-title":"Hepatology"},{"key":"514_CR66","doi-asserted-by":"publisher","first-page":"4839","DOI":"10.3748\/wjg.v13.i36.4839","volume":"13","author":"C Neumann-Haefelin","year":"2007","unstructured":"Neumann-Haefelin C, Spangenberg H-C, Blum H-E, Thimme R. Host and viral factors contributing to CD8+ T cell failure in hepatitis C virus infection. World J Gastroenterol. 2007;13:4839\u201347.","journal-title":"World J Gastroenterol"},{"key":"514_CR67","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1086\/315450","volume":"181","author":"NH Gr\u00fcner","year":"2000","unstructured":"Gr\u00fcner NH, Gerlach TJ, Jung MC, Diepolder HM, Schirren CA, Schraut WW, et al. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J Infect Dis. 2000;181:1528\u201336.","journal-title":"J Infect Dis"},{"key":"514_CR68","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1016\/j.ajpath.2011.08.004","volume":"179","author":"J Spahn","year":"2011","unstructured":"Spahn J, Pierce RH, Crispe IN. Ineffective CD8(+) T-cell immunity to adeno-associated virus can result in prolonged liver injury and fibrogenesis. Am J Pathol. 2011;179:2370\u201381.","journal-title":"Am J Pathol"},{"key":"514_CR69","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1089\/hum.2013.169","volume":"25","author":"V Ferreira","year":"2014","unstructured":"Ferreira V, Twisk J, Kwikkers K, Aronica E, Brisson D, Methot J, et al. Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPL(S447X)) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy. Hum Gene Ther. 2014;25:180\u20138.","journal-title":"Hum Gene Ther"},{"key":"514_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.991832","volume":"13","author":"X Li","year":"2022","unstructured":"Li X, Wei X, Lin J, Ou L. A versatile toolkit for overcoming AAV immunity. Front Immunol. 2022;13:991832.","journal-title":"Front Immunol"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00514-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00514-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00514-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T10:03:50Z","timestamp":1748253830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00514-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["514"],"URL":"https:\/\/doi.org\/10.1038\/s41434-025-00514-z","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,21]]},"assertion":[{"value":"4 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}